Ever Supreme Bio Technology Co. Ltd
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the… Read more
Ever Supreme Bio Technology Co. Ltd (6712) - Total Liabilities
Latest total liabilities as of June 2024: NT$261.37 Million TWD
Based on the latest financial reports, Ever Supreme Bio Technology Co. Ltd (6712) has total liabilities worth NT$261.37 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ever Supreme Bio Technology Co. Ltd - Total Liabilities Trend (2020–2023)
This chart illustrates how Ever Supreme Bio Technology Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ever Supreme Bio Technology Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Ever Supreme Bio Technology Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Beiren Robot System Co Ltd
SHG:688218
|
China | CN¥985.86 Million |
|
Multiconsult ASA
LSE:0R8N
|
UK | Nkr2.19 Billion |
|
Ningbo Jianan Electronics Co Ltd
SHE:300880
|
China | CN¥384.27 Million |
|
Zhejiang Jinfei Kaida Wheel Co Ltd
SHE:002863
|
China | CN¥6.25 Billion |
|
Shihlin Paper Corp
TW:1903
|
Taiwan | NT$5.04 Billion |
|
Shenzhen Zhongheng Huafa Co Ltd Class A
SHE:000020
|
China | CN¥328.31 Million |
|
Besalco Sa
SN:BESALCO
|
Chile | CL$1.05 Trillion |
Liability Composition Analysis (2020–2023)
This chart breaks down Ever Supreme Bio Technology Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ever Supreme Bio Technology Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ever Supreme Bio Technology Co. Ltd (2020–2023)
The table below shows the annual total liabilities of Ever Supreme Bio Technology Co. Ltd from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$232.96 Million | +28.39% |
| 2022-12-31 | NT$181.45 Million | +45.36% |
| 2021-12-31 | NT$124.83 Million | +60.94% |
| 2020-12-31 | NT$77.56 Million | -- |